JP5078100B2 - 循環癌細胞におけるステロイド受容体の検出および処置 - Google Patents
循環癌細胞におけるステロイド受容体の検出および処置 Download PDFInfo
- Publication number
- JP5078100B2 JP5078100B2 JP2009506735A JP2009506735A JP5078100B2 JP 5078100 B2 JP5078100 B2 JP 5078100B2 JP 2009506735 A JP2009506735 A JP 2009506735A JP 2009506735 A JP2009506735 A JP 2009506735A JP 5078100 B2 JP5078100 B2 JP 5078100B2
- Authority
- JP
- Japan
- Prior art keywords
- receptor
- cancer
- cancer cells
- immunoassay
- steroid receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010028980 Neoplasm Diseases 0.000 title claims description 93
- 201000011510 cancer Diseases 0.000 title claims description 79
- 108010085012 Steroid Receptors Proteins 0.000 title claims description 54
- 102000005969 steroid hormone receptors Human genes 0.000 title claims description 54
- 238000001514 detection method Methods 0.000 title claims description 18
- 210000004027 cell Anatomy 0.000 claims description 121
- 102100038595 Estrogen receptor Human genes 0.000 claims description 90
- 238000000034 method Methods 0.000 claims description 76
- 238000003018 immunoassay Methods 0.000 claims description 52
- 210000004369 blood Anatomy 0.000 claims description 40
- 239000008280 blood Substances 0.000 claims description 40
- 206010006187 Breast cancer Diseases 0.000 claims description 35
- 208000026310 Breast neoplasm Diseases 0.000 claims description 35
- 108090000468 progesterone receptors Proteins 0.000 claims description 31
- 102100032187 Androgen receptor Human genes 0.000 claims description 25
- 108010080146 androgen receptors Proteins 0.000 claims description 25
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 claims description 20
- 229910052707 ruthenium Inorganic materials 0.000 claims description 20
- 239000000284 extract Substances 0.000 claims description 18
- 230000035945 sensitivity Effects 0.000 claims description 16
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 14
- 108010041356 Estrogen Receptor beta Proteins 0.000 claims description 14
- 239000011324 bead Substances 0.000 claims description 13
- 108010007005 Estrogen Receptor alpha Proteins 0.000 claims description 12
- 230000008901 benefit Effects 0.000 claims description 11
- 210000001519 tissue Anatomy 0.000 claims description 10
- 229960002685 biotin Drugs 0.000 claims description 7
- 235000020958 biotin Nutrition 0.000 claims description 7
- 239000011616 biotin Substances 0.000 claims description 7
- 229940126588 endocrine therapeutic agent Drugs 0.000 claims description 7
- 210000004899 c-terminal region Anatomy 0.000 claims description 4
- 210000004897 n-terminal region Anatomy 0.000 claims description 3
- 210000002307 prostate Anatomy 0.000 claims description 3
- 102100025803 Progesterone receptor Human genes 0.000 claims 2
- 102100029951 Estrogen receptor beta Human genes 0.000 claims 1
- 101710196141 Estrogen receptor Proteins 0.000 description 54
- 102000003998 progesterone receptors Human genes 0.000 description 29
- 108010038795 estrogen receptors Proteins 0.000 description 27
- 238000000605 extraction Methods 0.000 description 16
- 239000002953 phosphate buffered saline Substances 0.000 description 16
- 238000003556 assay Methods 0.000 description 15
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 14
- 229940098773 bovine serum albumin Drugs 0.000 description 14
- 102000000509 Estrogen Receptor beta Human genes 0.000 description 13
- 241000283973 Oryctolagus cuniculus Species 0.000 description 12
- 239000012131 assay buffer Substances 0.000 description 12
- 238000001794 hormone therapy Methods 0.000 description 12
- 210000004881 tumor cell Anatomy 0.000 description 12
- 241000287828 Gallus gallus Species 0.000 description 11
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 11
- 210000003743 erythrocyte Anatomy 0.000 description 11
- 108010090804 Streptavidin Proteins 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 239000000427 antigen Substances 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 230000002055 immunohistochemical effect Effects 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 206010027476 Metastases Diseases 0.000 description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 7
- 238000009261 endocrine therapy Methods 0.000 description 7
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 description 7
- 238000002372 labelling Methods 0.000 description 7
- 210000000265 leukocyte Anatomy 0.000 description 7
- 239000006166 lysate Substances 0.000 description 7
- 206010060862 Prostate cancer Diseases 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 239000012083 RIPA buffer Substances 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 108091008039 hormone receptors Proteins 0.000 description 5
- 230000009401 metastasis Effects 0.000 description 5
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 4
- 239000004743 Polypropylene Substances 0.000 description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 239000003886 aromatase inhibitor Substances 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 239000012139 lysis buffer Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- -1 polypropylene Polymers 0.000 description 4
- 229920001155 polypropylene Polymers 0.000 description 4
- 239000001103 potassium chloride Substances 0.000 description 4
- 235000011164 potassium chloride Nutrition 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 229940122815 Aromatase inhibitor Drugs 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 101000882584 Homo sapiens Estrogen receptor Proteins 0.000 description 3
- 102000011931 Nucleoproteins Human genes 0.000 description 3
- 108010061100 Nucleoproteins Proteins 0.000 description 3
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 102000015694 estrogen receptors Human genes 0.000 description 3
- 239000011536 extraction buffer Substances 0.000 description 3
- 238000010324 immunological assay Methods 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 2
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 2
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000028180 Glycophorins Human genes 0.000 description 2
- 108091005250 Glycophorins Proteins 0.000 description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
- 102000007999 Nuclear Proteins Human genes 0.000 description 2
- 108010089610 Nuclear Proteins Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 229960002932 anastrozole Drugs 0.000 description 2
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229960000255 exemestane Drugs 0.000 description 2
- 229950011548 fadrozole Drugs 0.000 description 2
- 238000002875 fluorescence polarization Methods 0.000 description 2
- 229960002258 fulvestrant Drugs 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 229960003881 letrozole Drugs 0.000 description 2
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 229960001603 tamoxifen Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- 240000005020 Acaciella glauca Species 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102000049320 CD36 Human genes 0.000 description 1
- 108010045374 CD36 Antigens Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102100025470 Carcinoembryonic antigen-related cell adhesion molecule 8 Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 229940102550 Estrogen receptor antagonist Drugs 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000914320 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 8 Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 1
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 description 1
- 108010066302 Keratin-19 Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 108010013709 Leukocyte Common Antigens Proteins 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- WZSDNEJJUSYNSG-UHFFFAOYSA-N azocan-1-yl-(3,4,5-trimethoxyphenyl)methanone Chemical compound COC1=C(OC)C(OC)=CC(C(=O)N2CCCCCCC2)=C1 WZSDNEJJUSYNSG-UHFFFAOYSA-N 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 229940125697 hormonal agent Drugs 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 208000018821 hormone-resistant prostate carcinoma Diseases 0.000 description 1
- 102000011941 human estrogen receptor alpha Human genes 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000002122 magnetic nanoparticle Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 231100000324 minimal toxicity Toxicity 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 235000003499 redwood Nutrition 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/743—Steroid hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74501206P | 2006-04-18 | 2006-04-18 | |
| US60/745,012 | 2006-04-18 | ||
| PCT/US2007/066849 WO2007121459A2 (en) | 2006-04-18 | 2007-04-18 | Detection of steroid receptors on circulating carcinoma cells and treatment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009538415A JP2009538415A (ja) | 2009-11-05 |
| JP2009538415A5 JP2009538415A5 (enExample) | 2011-04-28 |
| JP5078100B2 true JP5078100B2 (ja) | 2012-11-21 |
Family
ID=38610453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009506735A Expired - Fee Related JP5078100B2 (ja) | 2006-04-18 | 2007-04-18 | 循環癌細胞におけるステロイド受容体の検出および処置 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20090291920A1 (enExample) |
| EP (1) | EP2008107A4 (enExample) |
| JP (1) | JP5078100B2 (enExample) |
| CA (1) | CA2647743A1 (enExample) |
| MX (1) | MX2008013331A (enExample) |
| WO (1) | WO2007121459A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4798801B2 (ja) * | 2004-10-06 | 2011-10-19 | ウェルスタット バイオロジクス コーポレイション | 循環する癌細胞におけるＨｅｒ−２／ｎｅｕタンパク質のレベルの上昇の検出および処置 |
| JP2010525326A (ja) * | 2007-04-19 | 2010-07-22 | ウェルスタット バイオロジックス コーポレイション | 分離されていない循環癌細胞由来のＨｅｒ−２／ｎｅｕタンパク質の上昇したレベルの検出および治療 |
| WO2009138130A1 (en) * | 2008-05-16 | 2009-11-19 | Atlas Antibodies Ab | Breast cancer prognostics |
| CA2804269A1 (en) * | 2010-07-07 | 2012-01-12 | The Regents Of The University Of Michigan | Diagnosis and treatment of breast cancer |
| DE102010027016A1 (de) | 2010-07-09 | 2012-01-12 | Universitätsklinikum Jena | Steroid-Styrylfarbstoff-Konjugate zur Simulation und direkten lichtoptischen Detektion des Verhaltens von Steroiden im lebenden biologischen Gewebe und in Gegenwart von steroidbindenden Proteinen |
| EP2628008B1 (en) * | 2010-10-14 | 2017-05-31 | Janssen Diagnostics, LLC | Methods and kits for the detection of circulating tumor cells in pancreatic patients using polyspecific capture and cocktail detection reagents |
| US20120252038A1 (en) * | 2011-04-01 | 2012-10-04 | Chianese David A | Steroid receptor assays |
| EP2888594B1 (en) | 2012-08-23 | 2018-08-15 | The Regents of the University of Colorado, a body corporate | Method for determining breast cancer treatment |
| US20150233932A1 (en) * | 2013-02-19 | 2015-08-20 | Ching-Ping Tseng | Methods, Systems, and Compositions for Enrichment of Rare Cells |
| IT201800004137A1 (it) * | 2018-03-30 | 2019-09-30 | Domenico Marina Di | Metodo di screening in vitro per diagnosi precoce dei tumori del cavo orale e relativo kit, basato in particolare su saggio elisa |
| SG11202106924VA (en) * | 2019-01-03 | 2021-07-29 | Meso Scale Technologies Llc | Compositions and methods for carrying out assay measurements |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020172987A1 (en) * | 1998-02-12 | 2002-11-21 | Terstappen Leon W.M.M. | Methods and reagents for the rapid and efficient isolation of circulating cancer cells |
| EP1360496A4 (en) * | 2001-02-16 | 2005-03-09 | Immunivest Corp | METHOD AND REAGENTS FOR THE QUICK AND EFFICIENT INSULATION OF CIRCULATING CANCER CELLS |
| EP1597353B1 (en) * | 2003-02-27 | 2010-11-24 | Veridex, LLC | CIRCULATING TUMOR CELLS (CTC's): EARLY ASSESSMENT OF TIME TO PROGRESSION SURVIVAL AND RESPONSE TO THERAPY IN METASTATIC CANCER PATIENTS |
| US7335735B2 (en) * | 2003-05-07 | 2008-02-26 | Cedars-Sinai Medical Center | Intracellular estradiol binding protein |
| JP4798801B2 (ja) * | 2004-10-06 | 2011-10-19 | ウェルスタット バイオロジクス コーポレイション | 循環する癌細胞におけるＨｅｒ−２／ｎｅｕタンパク質のレベルの上昇の検出および処置 |
| GB0512429D0 (en) * | 2005-06-17 | 2005-07-27 | Smithkline Beecham Corp | Novel compound |
| US20100105145A1 (en) * | 2005-07-01 | 2010-04-29 | Dako Denmark A/S | Method of simultaneously visualizing multiple biological targets |
| EP1816477A1 (en) * | 2006-02-06 | 2007-08-08 | F. Hoffmann-la Roche AG | The use of natriuretic peptides and placenta growth factor levels for risk stratification of individuals elected for cardiac stress testing |
-
2007
- 2007-04-18 CA CA002647743A patent/CA2647743A1/en not_active Abandoned
- 2007-04-18 MX MX2008013331A patent/MX2008013331A/es active IP Right Grant
- 2007-04-18 JP JP2009506735A patent/JP5078100B2/ja not_active Expired - Fee Related
- 2007-04-18 US US12/296,458 patent/US20090291920A1/en not_active Abandoned
- 2007-04-18 EP EP07760823A patent/EP2008107A4/en not_active Withdrawn
- 2007-04-18 WO PCT/US2007/066849 patent/WO2007121459A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| MX2008013331A (es) | 2008-11-10 |
| WO2007121459A3 (en) | 2009-04-09 |
| EP2008107A4 (en) | 2009-12-23 |
| CA2647743A1 (en) | 2007-10-25 |
| JP2009538415A (ja) | 2009-11-05 |
| WO2007121459A2 (en) | 2007-10-25 |
| US20090291920A1 (en) | 2009-11-26 |
| EP2008107A2 (en) | 2008-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5078100B2 (ja) | 循環癌細胞におけるステロイド受容体の検出および処置 | |
| JP4798801B2 (ja) | 循環する癌細胞におけるＨｅｒ−２／ｎｅｕタンパク質のレベルの上昇の検出および処置 | |
| JP5025724B2 (ja) | 循環腫瘍性細胞からのタンパク質の検出 | |
| JP2010525326A (ja) | 分離されていない循環癌細胞由来のＨｅｒ−２／ｎｅｕタンパク質の上昇したレベルの検出および治療 | |
| JP2010525326A5 (enExample) | ||
| Choesmel et al. | A relevant immunomagnetic assay to detect and characterize epithelial cell adhesion molecule‐positive cells in bone marrow from patients with breast carcinoma: immunomagnetic purification of micrometastases | |
| CN102656456B (zh) | 恶性肿瘤的诊断方法 | |
| CN111830249A (zh) | 用于纯化分离及分析非典型循环肿瘤细胞的方法的用途及非典型循环肿瘤细胞的用途 | |
| JP2009534666A (ja) | 循環内皮細胞の検出 | |
| Ferguson et al. | Defining the cell surface proteomic landscape of multiple myeloma reveals immunotherapeutic strategies and biomarkers of drug resistance | |
| JP2021531816A (ja) | 骨髄系由来サプレッサー細胞亜集団の検出および単離 | |
| WO2009120039A2 (en) | Use of cd9 for a target protein to develop anticancer drug of solid cancers that overexpress cd9 | |
| Wu et al. | Chronic stress-induced ANPEP drives liver cancer progression by increasing glutathione synthesis and inhibiting ferroptosis | |
| JP6195716B2 (ja) | 抗癌剤耐性診断マーカー | |
| WO2018168779A1 (ja) | 慢性閉塞性肺疾患バイオマーカー | |
| HK1103439B (en) | Detection of elevated levels of her-2/neu protein on circulating cancer cells and treatment | |
| JP2025172327A (ja) | がんのバイオマーカー、それに対する抗体、抗体を用いたがん患者の予後の予測方法、および、がんの検出方法 | |
| CN101122603A (zh) | 可溶性协同信号分子在检测类风湿关节炎中的用途 | |
| Grammatoglou et al. | Immunohistochemical Investigation of TMSG-1 Protein in Colorectal Cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100310 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100310 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110301 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110530 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20110601 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110829 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110905 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110914 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120124 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120308 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120823 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120824 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150907 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |